Patents for A61P 35 - Antineoplastic agents (221,099)
09/2002
09/18/2002CN1370074A Method of treating malignancies and viral infections and improving immune function with dietary supplement
09/18/2002CN1370068A Pharmaceutical agent comprising benzamide derivative as active ingredient
09/18/2002CN1369301A External-applied Chinese medicine for treating external phyma
09/18/2002CN1369272A Anticancer medical wine
09/18/2002CN1091092C Retionic acid x-receptor ligands, its compsn. and usage
09/18/2002CN1090971C Uropoly acid-peptide compsn.
09/18/2002CN1090970C Process for preparing uropoly acid-peptide compsn.
09/18/2002CN1090964C Powered medicine for treating liver cancer, gastric cancer, lung cancer and esophags cancer
09/18/2002CN1090937C Prepn. of EIA-specicial medicinal compond for making medicine for resisting heat-cervical tumor and its application
09/17/2002US6452037 Carbonylated, oligoanilinated derivatives; antitumor agents; photosensitizers transforming molecular oxygen into singlet oxygen; bioavailable
09/17/2002US6452025 Three-step conversion of protected taxane ester to paclitaxel
09/17/2002US6451994 Polypeptides, polynucleotides; drug screening; diagnosing alzheimer*s, parkinson*s, huntington*s, and creutzfelt-jacob disease; amyotrophic lateral sclerosis, cystic fibrosis
09/17/2002US6451981 Inhibitor of cellular adhesion, migration or infiltration into areas of tissue damage, injury, or transplant
09/17/2002US6451976 Bi-or multifunctional molecules based on a dendroaspin scaffold
09/17/2002US6451971 Polypeptide cell adhesion inhibitors; antimetastasis and anticarcinogenic agents
09/17/2002US6451968 Hoogsteen type base pairing in triplex motif; diagnosis; heat resistance; detection of point mutations, restriction enzyme sites, and transcription inhibition
09/17/2002US6451849 Use of hydroxymatairesinol for prevention of cancers, non-cancer, hormone dependent diseases and cardiovascular diseases by hydroxymatairesinol, and a pharmaceutical preparation, food additive and food product comprising hydroxymatairesinol
09/17/2002US6451838 1-(pyrrolidin-1-ylmethyl)-3-(pyrrol-2-ylmethylidene)-2-indolinone derivatives
09/17/2002US6451834 Indeno[1,2-c]-, naphtho[1,2-c]- and benzo[6,7]cyclohepta[1,2-c]pyrazole derivatives
09/17/2002US6451824 Sulfonylaminocarboxylic acids
09/17/2002US6451810 Amide substituted imidazoquinolines
09/17/2002US6451804 Heteroalkylamino-substituted bicyclic nitrogen heterocycles
09/17/2002US6451803 N-acyl and n-aroyl aralkyl amides useful in treating seritonergic disorders
09/17/2002US6451794 2,3-Diaryl-pyrazolo[1,5-b]pyridazines derivatives, their preparation and their use as cyclooxygenase 2(COX-2) inhibitors
09/17/2002US6451791 Amidoaromatic ring sulfonamide hydroxamic acid compounds
09/17/2002US6451785 Beta lactams as antiproliferative agents
09/17/2002US6451779 Composition and method for contraception and treatment of tumors of the mammary glands
09/17/2002US6451776 Water soluble prodrugs of hindered alcohols
09/17/2002US6451765 Methods for treating breast cancer using Mammastatin
09/17/2002US6451579 Regulated expression of recombinant proteins using RNA viruses
09/17/2002US6451523 Variant form of the receptor for the obese gene product. the invention relates to methods of detecting this receptor variant in cells and tissues of obese individuals.
09/17/2002US6451318 Secreted proteins
09/17/2002US6451316 Incubating t-cells and antigen presenting cells in vitro with purified complex of heat shock protein and antigen; generating cd4 cells; immunotherapy, anticarcinogenic agents
09/17/2002US6451312 Diagnosis, imaging; induction of endothelial cell surface antigens
09/17/2002US6451311 An antibody which binds procalcitonin but not free calcitonin, free katacalcin and free n-procalcitonin; used as an in vitro or in vivo diagnostic agent
09/17/2002US6451310 Preventing t cell activation of b cells by administering antibody cabable of binding protein recognized by monoclonal antibody 5c8
09/17/2002US6451307 3′-exonuclease, production and use thereof
09/17/2002US6451305 Methods for stimulating T cell responses to tumor cells expressing LFA-3 and a CD28 or CTLA4 ligand
09/17/2002US6451284 Antibodies which target lymphoma cells which have a tendency to localize to the bone marrow.
09/17/2002CA2243459C Human antibodies that bind human tnf.alpha.
09/17/2002CA2213001C Isolated nucleic acid molecule encoding peptides which form complexes with mhc molecule hla-cw*1601 and uses thereof
09/17/2002CA2187908C Non-splicing variants of gp350/220
09/17/2002CA2085598C 1,2-dihydro-3h-dibenzisoquinoline-1,3-dione anticancer agents
09/17/2002CA2067919C Heterobifunctional antibodies possessing dual catalytic and specific antigen binding properties and methods using them
09/17/2002CA2057338C Diarylfluoromethane compounds
09/17/2002CA2041832C Hydrazones
09/16/2002CA2376844A1 Pyrazolo¢4,3-d!pyrimidin-7-ones and pyrazolo¢3,4!pyrimidin-4-ones and purinones which inhibit cgmp pdes
09/12/2002WO2002070748A2 Response of dendritic cells to a diverse set of pathogens
09/12/2002WO2002070747A1 Method of molecular diagnosis of chronic myelogenous leukemia
09/12/2002WO2002070742A1 Method for the development of gene panels for diagnostic and therapeutic purposes based on the expression and methylatoin status of the genes
09/12/2002WO2002070741A2 Methods, systems and computer program products for determining the biological effect and/or activity of drugs, chemical substances and/or pharmaceutical compositions based on their effect on the methylation status of the dna
09/12/2002WO2002070700A1 Polynucleotide useful for modulating cancer cell proliferation
09/12/2002WO2002070677A2 Palmityl transferases
09/12/2002WO2002070676A2 Use of protein histidine phosphatase
09/12/2002WO2002070675A2 Regulation of human histone acetyltransferase
09/12/2002WO2002070669A2 Secreted proteins
09/12/2002WO2002070563A2 Nuclear hormone receptor ligand binding domain
09/12/2002WO2002070562A2 Nuclear hormone receptor ligand binding domain
09/12/2002WO2002070561A2 Nuclear hormone receptor ligand binding domain
09/12/2002WO2002070560A2 Nuclear hormone receptor ligand binding domain
09/12/2002WO2002070559A2 Nuclear hormone receptor ligand binding domains
09/12/2002WO2002070558A2 Nuclear hormone receptor ligand binding domain
09/12/2002WO2002070557A2 Nuclear hormone receptor ligand binding domain
09/12/2002WO2002070556A1 POLYPEPTIDE OF A P53 PROTEIN-SPECIFIC MURINE Α/β T-CELL RECEPTOR, NUCLEIC ACIDS CODING THEREFOR AND USE THEREOF
09/12/2002WO2002070555A2 Method of modulating the proliferation of medullary thyroid carcinoma cells
09/12/2002WO2002070553A1 Tumour peptide antigen produced from human mdm2 proto-oncogene
09/12/2002WO2002070549A2 Chimeric polypeptides of serum albumin and uses related thereto
09/12/2002WO2002070547A1 Template-fixed peptidomimetics with antimicrobial activity
09/12/2002WO2002070532A2 C2,5'-disubstituted and n6,c2,5'-trisubstituted adenosine derivatives and their different uses
09/12/2002WO2002070525A2 Nitrogen-based camptothecin derivatives
09/12/2002WO2002070521A1 Novel metalloproteinase inhibitor derivatives, method for preparing same and pharmaceutical compositions containing them
09/12/2002WO2002070515A2 Chromane derivatives, process for their preparation and their use as antitumor agents
09/12/2002WO2002070511A1 Compounds useful as modulators of melanocortin receptors and pharmaceutical compositions comprising same
09/12/2002WO2002070502A1 Dimeric isoflavones
09/12/2002WO2002070498A1 Methods for preparing new taxoids and pharmaceutical compositions containing them
09/12/2002WO2002070496A1 Nitric oxide donors based on metallic centres
09/12/2002WO2002070494A1 Aryl and heteroaryl urea chk1 inhibitors for use as radiosensitizers and chamosensitizers
09/12/2002WO2002070493A1 Bisaryl derivatives having fsh receptor modulatory activity
09/12/2002WO2002070485A1 Substituted 2-thio-3,5-dicyano-4-aryl-6-aminopyridines and their use as adenosine receptor-selective ligands
09/12/2002WO2002070484A1 Substituted 2-oxy-3,5-dicyano-4-aryl-6-aminopyridines and use thereof
09/12/2002WO2002070480A1 Glutarimide derivatives as therapeutic agents
09/12/2002WO2002070478A1 Indolone derivatives having vascular-damaging activity
09/12/2002WO2002070473A2 Carboxamide derivatives as therapeutic agents
09/12/2002WO2002070471A1 Phenyl derivatives and their use in the treatment of thromboembolic disorders or tumours
09/12/2002WO2002070468A2 Novel benzamidine derivatives having anti-inflammatory and immunosuppressive activity
09/12/2002WO2002070467A1 Derivatives of diphenylurea, diphenyloxalic acid diamide and diphenylsulfuric acid diamide and their use as medicaments
09/12/2002WO2002070068A2 Lipoxin analogs as novel inhibitors of angiogenesis
09/12/2002WO2002070023A2 Compositions comprising bone marrow cells together with demineralized and/or mineralized bone matrix and uses thereof in the induction of bone and cartilage formation
09/12/2002WO2002070008A1 Combination methods of inhibiting tumor growth with a vascular endothelial growth factor receptor antagonist
09/12/2002WO2002070003A1 Altered peptide ligands
09/12/2002WO2002069999A1 Stable aqueous solutions of granulocyte macrophage colony-stimulating factor
09/12/2002WO2002069998A1 Regulating vegf expression by a protein of the tis11 family
09/12/2002WO2002069995A2 Use of trail and antiprogestins for treating cancer
09/12/2002WO2002069990A1 Method of treating tumor and consignment system of proliferating and processing activated lymphocytes to be used in parallel to pdt
09/12/2002WO2002069988A2 Compositions comprising bone marrow cells together with demineralized and/or mineralized bone matrix and their use in bone marrow transplantation
09/12/2002WO2002069977A1 Use of certain steroids for treatment of blood cell deficiencies
09/12/2002WO2002069970A1 Substituted 8-arylquinoline phosphodiesterase-4 inhibitors
09/12/2002WO2002069965A1 Benzimidazole derivatives as therapeutic agents
09/12/2002WO2002069961A1 Il-8 receptor ligands-drugs for inflammatory and autoimmune diseases
09/12/2002WO2002069955A1 Method and formula for anti-tumor and anti-matastatic effect